原尚股份(603813.SH):部分董事、高管拟合计减持不超7.35万股
格隆汇5月20日丨原尚股份(603813.SH)公告,部分董事、高级管理人员因个人资金需求拟减持股份。其中,李运拟减持股份不超过4.5万股,即不超过公司总股本的0.0502%;余奕宏拟减持股份不超过2.85万股,即不超过公司总股本的0.0318%,减持价格将根据减持时的市场价格确定。李运、余奕宏均通过上海证券交易所集中竞价的交易方式减持,减持期间为自本公告日起15个交易日后的6个月内(2020年06月11日至2020年11月10日),若在减持计划实施期间公司发生派发红利、转增股本等股本除权、除息事项的,将根据股本变动对减持数量、减持价格进行相应调整,并在窗口期内不得减持股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.